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Getting drug doses right in children with
tuberculosis (TB)
H. McIlleron
University of Cape Town, Cape Town, South Africa
New drugs that could revolutionize the treatment of drug-
sensitive anddrug-resistant TB are imminently available.Moreover
recent research of pharmacokinetic-pharmacodynamic relation-
ships in adults suggests that the doses of some currently used
drugs should be changed. It is imperative that children access these
improvements to TB treatment without delay.
It is likely that children will respond well to a TB regimen if
given drug formulations and doses that achieve comparable phar-
macokinetics to those in adults. Recent changes to theWHO-dosing
guidelines for the ﬁrst line TB drugs in children acknowledge that
the traditional approach to pediatric dosing (using mg/kg doses
approximating those in adults) resulted in under-dosing of chil-
dren fordecades. Efﬁcientpharmacokinetic studies arenecessary to
support safe and effective doses for children. Contemporarymodel-
based pharmacometric analyses facilitate efﬁcient studies, pooling
of data across different studies, and prediction of pragmatic dosing
approaches.
Pediatric studies designed to describe the pharmacokinetics of
new drugs need to be conducted during drug development, typi-
cally as soon as phase 2b studies in adults have been completed.
The studies should include sufﬁcient data in children across the
range of ages, and should preferably be conducted in the target
pediatric populationusing appropriate child-friendly formulations,
which should be developed early.
Treatment preparation and administration methods practiced
by caregivers of infants and young children could affect the sta-
bility and bioavailability of the drugs administered. There is little
knowledge of these practices, or treatment acceptability and taste
preferences, which should be taken into account when developing
suitable formulationsandpragmatic adviceondoseadministration.
Drug-drug interactions complicate the management of HIV and
other comorbid conditions in children with TB. As the magnitude
of pharmacokinetic drug-drug interactions may not be predicted
by adult studies, studies in children are required to guide dose
adjustments.
The optimization of doses and formulations for children will
improve care and cannot continue to be neglected.
http://dx.doi.org/10.1016/j.ijid.2014.03.535
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Lost in translation - what next for studies of
new TB vaccines for children?
B. Kampmann
Imperial College London and MRC Unit, The Gambia,
London, United Kingdom
Professor Kampmann leads a research team of clinicians and
scientists in theUKandWestAfrica. Her grouphas beenworking on
the difﬁcult problem of childhood tuberculosis and has evaluated
immune responses to natural infection and vaccination, including
novel diagnostics. Her overviewpresentation todaywill summarise
recent accomplishments in thedevelopmentofnewvaccineagainst
TB, why these might or might not work and what lessons can be
learned from the recent Phase IIb trial of a new anti-TB vaccine in
South Africa, which unfortunately- or maybe predictively- did not
show any protective efﬁcacy in young children. She will present
her thoughts on where this leaves the ﬁeld now and what the next
steps might be. She would not expect that everyone agrees.
http://dx.doi.org/10.1016/j.ijid.2014.03.536
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Whole-genome sequencing for TB drug
resistance determination
S.V. Omar1,∗, J. Featherston2, H. Said1, Z. Bhyat1,
A. Dreyer1, J. Rees2, N. Ismail1
1 National Institute for Communicable Diseases,
Johannesburg, South Africa
2 Agricultural Research Council, Pretoria, South
Africa
Background: South Africa remains challenged with a high
Tuberculosis burden accompanied by a steady increase in drug-
resistant cases. The introductionof twomolecularmethodsover the
past ﬁve year has improved the detection of drug-resistant cases,
however, providing information for only one or two drugs used
for ﬁrst-line treatment. In this study we access the usefulness of
Whole Genome Sequencing (WGS) for Drug Resistance determina-
tion of both ﬁrst and second line drugs used for the treatment of M.
tuberculosis in high burdened South Africa
Methods & Materials: Pilot work involved WGS on a set of
twenty M. tuberculosis isolates with known phenotypic resistance
proﬁles on liquid medium. Sequencing was carried out using the
MiSeq next-generation sequencer (Illumina), library preparation
was performed using the NexteraXT kit and sequencing using
the version 2 kit (500 cycle). Sequence analysis was carried out
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using theCLCGenomicsWorkbenchV6.0.1.Genomesweremapped
against the annotated M. Tuberculosis H37Rv (Sanger Institute)
as the reference genome and Quality-based Variant Detection
analysis was performed to determine any differences in the resis-
tance associated genes (mutated) compared to the reference
genome (wild-type). Analysis was performed on genes associ-
atedwith rifampicin, isoniazid, ﬂuoroquinilones and pyrazinimide.
High probability mutations were identiﬁed using the TBDREAM
database.
Results: Samples sequenced had an average depth ofmore than
40x coverage with Q-scores greater 30 and achieving more than
99.9% coverage of the genes of interest. Correlation between the
phenotypic and the genotypic method was excellent.
Conclusion: The use ofWGS for the detection of drug resistance
is fairly rapid and accurate with comprehensive information for
several genetic targets at once. This may become a resourceful tool
to determine ideal therapy of patients infectedwithM. tuberculosis.
http://dx.doi.org/10.1016/j.ijid.2014.03.537
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Characteristics and treatment outcomes of MDR
tuberculosis in Taiwan
M.-C. Yu1, H.-Y. Chen2, S.-H. Chien1, R. Jou2,∗
1 Wan Fang Hospital, Taipei Medical University,
Taipei, Taiwan, R.O.C.
2 Centers for Disease Control, Taipei, Taiwan, R.O.C.
Background: In Taiwan, the MDR-TB among new TB cases was
1%, and 6% in retreated TB cases. Facing the challenge of MDR-TB,
a designated government-organized and hospital-initiated with an
enhanced direct observed treatment program was implemented in
May2007 toprovidepatient-centered care andbettermanagement
for MDR-TB cases. In this study, we investigated characteristics of
MDR-TB cases notiﬁed in 2007-2009 in northern Taiwan and iden-
tiﬁed possible risk factors associated with treatment outcomes.
Methods & Materials: In 2007-2009, 151 MDR-TB cases were
conﬁrmed. Demographic, clinical characteristics of patients and
bacteriological and genetic data of Mycobacterium tuberculosis
strains were analyzed. The treatment outcome at 30 months was
evaluated. Comparisons were performed using Mantel-Haenszel
chi-squared method or Fisher’s exact. Statistical signiﬁcance was
deﬁned as a p value <0.05.
Results: Of the 151 MDR-TB cases, 106 (70.2%) were males and
45 (29.8%) females with a mean age of 52.0 and 45.4 years old,
respectively. Of the 151 MDR-TB cases, 54.3% were new cases and
23.2% cases were either pre-XDR or XDR cases. Among 39.7% of
cases with comobility, 25.8% had diabetes mellitus. Furthermore,
49.5% of patients were infected with Beijing genotype strains and
23.8%were resulted from recent transmission. Outcomewas deter-
mined for 126 (83.4%) cases enrolled in a government-organized
and hospital-initiated MDR-TB treatment consortium. Excluding
two cases transferred out, 85.5% had favorable outcome and 18 had
unfavorable outcomes including 16 death and 2 failure cases with
severe complications due to anti-TBmedication.We found that age
group elder than 65 years old (p <0.01), BMI <18.5 (p =0.01), M.
tuberculosis strains resistant to streptomycin (p=0.02)were factors
for unfavorable treatment outcome.
Conclusion: High proportion ofnew MDR-TB cases suggesting
the need for stringent control measures including early diagno-
sis, and strengthened contact tracing strategies. Nevertheless, a
designated patient-center management program adopting indi-
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HIV and HBV infection in Cameroonian
university context: Case of the University of
Dschang
M. Sanou Sobze1, J.-F. Onohio1,∗, J. Fokam2, B.
Donfack1, P. M. Nkamedjie Pete1, G. B. Djeunang
Dongho1, V. Colizzi3, G. Russo4
1 Faculty of Sciences; University of Dschang,
Dschang, Cameroon
2 Chantal Biya International Reference Centre
(CIRCB) for research on HIV/AIDS prevention and
management, Yaoundé, Cameroon
3 University of Rome “Tor Vergata”, Rome, Italy
4 Sapienza University of Rome, Rome, Italy
Background: In sub-Saharan Africa HIV infection remains
largely epidemic, whereas HBV infection is highly endemic (> 8%).
In Cameroon, HIV and HBV prevalence is 4.3% and ≥ 10% respec-
tively. Teenagers and young adults, including university students,
are the population groupsmostly affected. Epidemiological data on
HIV and HBV infection among university students could be helpful
to implement speciﬁc prevention strategies.
Methods & Materials: A descriptive study was performed in
May 2013 among 624 students from the University of Dschang,
Cameroon. Participants were screened for HIV and HBV infection
and a standard questionnaire was administered.
Results: The average age of participants was 23.3 years (=3.2)
with a female predominance (58.7%). The observed prevalence
of HIV and HBV infection was 1.1% (7/624) and 2.8% (5/176)
respectively. 83.2% of participantswere sexually active. Concerning
sexual risky behaviours, participants reported having multipart-
ners (10.9%), using condom regularly (36.4%) or occasionally
(58.5%). 100% and 62.8% reported to be aware on HIV or HBV infec-
tion respectively. In addition, 64.4% and 5.5% of the participants
were aware of their HIV or HBV status respectively. The excessive
cost of HBsAg has been identiﬁed as the major barrier to testing
(87.6%).
Conclusion: Among college Cameroonian students the preva-
lence of HIV and HBV infection seems to be relatively low if
compared to general population. Anyhow, having multiple sexual
partner together with the non systematic use of condom dur-
ing sexual intercourse represent risky behaviours among students.
Awareness campaigns and screening facilitation on HBV infection
among students need to be strengthened.
http://dx.doi.org/10.1016/j.ijid.2014.03.539
